Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02931565 · ClinicalTrials.gov registry record · Phase 2
Study of IW-1701, A Stimulator of Soluble Guanylate Cyclase (sGC), in Patients With Type I or II Achalasia
A Phase 2 study, sponsored by Cyclerion Therapeutics.
- Terminated
- Registry status
- Phase 2
- Development phase
- 9
- Enrollment target
NCT02931565: Clinical Trial Phase 2 study, sponsored by Cyclerion Therapeutics.
NCT02931565 is a Phase 2 study that was terminated before completion, run by Cyclerion Therapeutics. The registered enrollment target is 9 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (93% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02931565, a Phase 2 study, was terminated before completion, sponsored by Cyclerion Therapeutics.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 9 participants
- Enrollment target
Study Summary
The objectives of this study are as follows: In participants with primary Type I or II achalasia, following a single 5-mg dose of olinciguat (IW-1701), * To assess the safety and tolerability * To determine the effects on measures of esophageal function by high-resolution impedance manometry (HRIM) * To determine the pharmacokinetic (PK) parameters
Primary Outcome
An adverse event (AE) is any untoward medical occurrence, which does not necessarily have to have a causal relationship with study treatment. An SAE is any AE occurring at any dose that results in any of the following outcomes: death; life-threatening: the patient was at immediate risk of death from the reaction as it occurred; hospitalization or prolongation of existing hospitalization; persistent or significant disability/incapacity; congenital anomaly/birth defect; important medical event. De
Interventions
- DRUG Matching Placebo
- DRUG Olinciguat
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2017-04-06 |
| Est. Completion | 2018-05-01 |
| Phase | Phase 2 |
Why NCT02931565 stopped before completion
NCT02931565 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 9 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (93% lower).
The record links to 0 conditions, and to 2 interventions - of which Matching Placebo is the first listed.
NCT02931565 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02931565 about?
NCT02931565 is a clinical study titled "Study of IW-1701, A Stimulator of Soluble Guanylate Cyclase (sGC), in Patients With Type I or II Achalasia". The objectives of this study are as follows: In participants with primary Type I or II achalasia, following a single 5-mg dose of olinciguat (IW-1701), * To assess the safety and tolerability * To determine the effects on measures of esophageal function by high-resolution impedance manometry (HRIM...
What is the current status of trial NCT02931565?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 9 participants. The study started on 2017-04-06. Estimated completion is 2018-05-01.
What interventions are being tested in trial NCT02931565?
The interventions under investigation include: Matching Placebo (DRUG), Olinciguat (DRUG).
Who is sponsoring clinical trial NCT02931565?
This trial is sponsored by Cyclerion Therapeutics, which has 11 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02931565's enrollment target sits among peer trials
9 1989th of 2000 higher than 11 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI